Arbutus Biopharma Corporation Common Stock
$5.04
-$0.04 (-0.69%)
$5.00Day Range$5.06
Key Statistics
Market Cap
$1.00B
Shares Outstanding
198.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 26, 2007
Round Lot
100
Locale
US
Trading Data
Day Open
$5.04
Day High
$5.06
Day Low
$5.00
Volume
2.56M
VWAP
$5.03
Prev Close
$5.07
Transactions
--
Acc. Volume
--
About Arbutus Biopharma Corporation Common Stock
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
PHARMACEUTICAL PREPARATIONSSIC 283419 employees701 VETERANS CIRCLE, WARMINSTER, PA, 18974604-419-3200IPO Jul 26, 2007US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001447028
- Composite FIGI
- BBG000RR8V85
- Share Class FIGI
- BBG001S6RSK0
- Ticker Root
- ABUS
- SIC Code
- 2834
About Arbutus Biopharma Corporation Common Stock (ABUS) Stock
Arbutus Biopharma Corporation Common Stock (ABUS) closed the 2026-09-18 session at $5.04, down 0.69% versus the previous close (-0.04). The stock opened at $5.04 and traded between $5.00 and $5.06 during that session. Session trading volume was 2.6M shares. The volume-weighted average price (VWAP) is $5.03.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Arbutus Biopharma Corporation Common Stock has a market capitalization of $1.00 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ABUS is listed on the XNAS exchange. The company employs approximately 19 people. Arbutus Biopharma Corporation Common Stock is headquartered in WARMINSTER, PA. The recorded listing date is 2007-07-26.
On this page you can find market ABUS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.